{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:20:27Z","timestamp":1793146827079,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enhancer of zeste homolog 2 (EZH2) is a transcriptional enzyme implicated in tumor development and is often correlated to poor patient outcomes in various malignancies. The study evaluated various methods for EZH2 expression in lip and ear squamous cell carcinomas (LSCC, ESCC) by matching patients with and without lymph node metastasis (LNM) and further analysis of clinical outcome parameters. EZH2 inhibition therapy has shown promising results in multiple cancer entities, with ongoing research exploring its potential in other malignancies. This approach may also be applicable to high-risk LSCC and ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 122 patients who had been surgically treated for LSCC and ESCC were selected to form LNM-positive and LNM-negative matched pairs. EZH2 expression has been examined after immunostaining of the tumor tissue with EZH2-antibodies and quantified as extent, intensity, and score. Pursuing the clinical benefit, we analyzed three different EZH2-score approaches to determine aberrations in EZH2 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While the overall EZH2 extent did not correlate with clinical outcome, the EZH2-intensity and -score was lower in patients who developed a local relapse or distant metastasis (DM). High EZH2-scores correlated with increasing grading, pN-, and American Joint Committee on Cancer-stage. Overall, the carcinoma tissue samples showed a high expression of EZH2 (mean expression &amp;gt; 60%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The hypothesis of the predictive prognostic contribution of EZH2 in clinical decisions regarding the occurrence of LNM was not substantiated by our data. Nevertheless, the elevated expression of EZH2 we have observed in our findings could be utilized as a pretherapeutic assessment prior to targeted therapies with tazemetostat. Subsequent research should substantiate this hypothesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2024.1438021","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T05:50:00Z","timestamp":1741672200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["EZH2: An analysis of a potential new tumor marker in high-risk localization of cutaneous squamous cell carcinomas"],"prefix":"10.3389","volume":"14","author":[{"given":"Cristian-Viktor","family":"Valea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hallermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Dirk","family":"Raguse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wermker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.046","article-title":"Cutaneous squamous cell carcinoma (SCC) of the head and neck: Risk factors of overall and recurrence-free survival","volume":"46","author":"Kyrgidis","year":"2010","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.762","article-title":"Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012: empirical relationships","volume":"150","author":"Xiang","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0437-2_7","article-title":"Epidemiology of skin cancer","volume":"810","author":"Leiter","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer: Worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"B5","article-title":"Pre-cancerous lesions in the oral and maxillofacial region: A literature review with special focus on etiopathogenesis","volume":"11","author":"Irani","year":"2016","journal-title":"Iran J Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2015.02.002","article-title":"Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer","volume":"43","author":"Wermker","year":"2015","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14072","article-title":"S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) \u2013 short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease","volume":"18","author":"Leiter","year":"2020","journal-title":"JDDG: J der Deutschen Dermatologischen Gesellschaft"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2010.03593.x","article-title":"A retrospective analysis of histological prognostic factors for the development of lymph node metastases from auricular squamous cell carcinoma: Auricular SCC prognostic factors","volume":"57","author":"Clark","year":"2010","journal-title":"Histopathology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.circen.2015.11.005","article-title":"Clinical characteristics of Malignant tumours originating in the external ear","volume":"83","author":"Gallegos-Hern\u00e1ndez","year":"2015","journal-title":"Cirug\u00eda y Cirujanos (English Edition)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.05.036","article-title":"Dermatologic diseases of the external ear","volume":"32","author":"\u00d6zt\u00fcrkcan","year":"2014","journal-title":"Clinics Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24843","article-title":"High-risk squamous cell carcinoma of the ear \u2014 A potential role for sentinel node biopsy","volume":"39","author":"Beecher","year":"2017","journal-title":"Head Neck"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2021.05.007","article-title":"Immune checkpoint analysis in lip cancer","volume":"49","author":"Klein","year":"2021","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441306","article-title":"Cutaneous squamous-cell carcinoma","volume":"344","author":"Murad","year":"2001","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164087","article-title":"IMP3 expression as a potential tumour marker in high-risk localisations of cutaneous squamous cell carcinoma: IMP3 in metastatic cSCC","volume":"15","author":"Klein","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3142","article-title":"Cytoplasmic methylation fuels leukocyte invasion","volume":"16","author":"Wehrle-Haller","year":"2015","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-13-0546","article-title":"EZH2: not EZHY (Easy) to deal","volume":"12","author":"Deb","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B17","article-title":"Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology","volume":"5","author":"Su","year":"2015","journal-title":"Am J Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2147","article-title":"EZH2-targeted therapies in cancer: hype or a reality","volume":"80","author":"Eich","year":"2021","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.oraloncology.2015.11.002","article-title":"EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity","volume":"52","author":"Chang","year":"2016","journal-title":"Oral Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13148-021-01045-1","article-title":"Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors","volume":"13","author":"Li","year":"2021","journal-title":"Clin Epigenet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-020-01209-0","article-title":"Differential expression of EZH2 and H3K27me3 in oral verrucous carcinoma and oral verrucous hyperplasia","volume":"15","author":"Sihavong","year":"2021","journal-title":"Head Neck Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9518","article-title":"Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13148-017-0390-y","article-title":"Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas","volume":"9","author":"Lindsay","year":"2017","journal-title":"Clin Epigenet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"33720","DOI":"10.18632\/oncotarget.5606","article-title":"Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25836","article-title":"MiR-101-3p regulates the viability of lung squamous carcinoma cells via targeting EZH2","volume":"118","author":"Hou","year":"2016","journal-title":"J Cell Biochem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.gene.2015.11.045","article-title":"miR-340 impedes the progression of laryngeal squamous cell carcinoma by targeting EZH2","volume":"577","author":"Yu","year":"2016","journal-title":"Gene"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4704","article-title":"EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells","volume":"12","author":"Huang","year":"2016","journal-title":"Oncol Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25031","article-title":"High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy","volume":"127","author":"He","year":"2010","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgab091","article-title":"EZH2 knockout in oral cavity basal epithelia causes more invasive squamous cell carcinomas","volume":"42","author":"Baquero","year":"2021","journal-title":"Carcinogenesis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1610-0387.2008.06706.x","article-title":"Short German guidelines: Squamous cell carcinoma","volume":"6","author":"Breuninger","year":"2008","journal-title":"JDDG: J der Deutschen Dermatologischen Gesellschaft"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12673","article-title":"EZH2 overexpression in head and neck cancer is related to lymph node metastasis","volume":"47","author":"Nienstedt","year":"2018","journal-title":"J Oral Pathol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaoto.2016.3455","article-title":"Epidemiology of squamous cell carcinoma of the lip in the United States: A population-based cohort analysis","volume":"142","author":"Han","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e2683","DOI":"10.1097\/GOX.0000000000002683","article-title":"Nonmelanoma skin cancers: embryologically relevant sites and UV exposure","volume":"8","author":"Nicoletti","year":"2020","journal-title":"Plast Reconstructive Surg - Global Open"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/1746-160X-4-2","article-title":"Cutaneous lesions of the external ear","volume":"4","author":"Sand","year":"2008","journal-title":"Head Face Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/DSS.0000000000001020","article-title":"Squamous cell carcinoma of the lip\u2014a review of squamous cell carcinogenesis of the mucosal and cutaneous junction","volume":"43","author":"Bota","year":"2017","journal-title":"Dermatologic Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.5863","article-title":"GSK126 (EZH2 inhibitor) interferes with ultraviolet A radiation\u2212induced photoaging of human skin fibroblast cells","volume":"15","author":"Qin","year":"2018","journal-title":"Exp Ther Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.2219","article-title":"Increased expression of enhancer of Zeste Homolog 2 (EZH2) differentiates squamous cell carcinoma from normal skin and actinic keratosis","volume":"24","author":"Xie","year":"2014","journal-title":"Eur J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24291","article-title":"Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage","volume":"9","author":"Caruso","year":"2018","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012946107","article-title":"A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage","volume":"107","author":"Chou","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4161\/cc.25795","article-title":"Polycomb repressive complex 2 contributes to DNA double-strand break repair","volume":"12","author":"Campbell","year":"2013","journal-title":"Cell Cycle"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/path.4416","article-title":"Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer\u2013host interface","volume":"234","author":"Bronsert","year":"2014","journal-title":"J Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3478","article-title":"A mechanically active heterotypic E-cadherin\/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion","volume":"19","author":"Labernadie","year":"2017","journal-title":"Nat Cell Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e51239","DOI":"10.1371\/journal.pone.0051239","article-title":"PRC2\/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation","volume":"7","author":"Yu","year":"2012","journal-title":"In Situ. PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/gad.181800.111","article-title":"EZH2 couples pancreatic regeneration to neoplastic progression","volume":"26","author":"Mallen-St. Clair","year":"2012","journal-title":"Genes Dev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.19108","article-title":"Ezh2 acts as a tumor suppressor in kras-driven lung adenocarcinoma","volume":"13","author":"Wang","year":"2017","journal-title":"Int J Biol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2003.08.007","article-title":"Management of patients with squamous cell carcinoma of the lower lip and N0-neck","volume":"32","author":"Bucur","year":"2004","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2017.07.007","article-title":"Sentinel lymph node biopsy for oral squamous cell carcinoma. Where are we now","volume":"55","author":"Schilling","year":"2017","journal-title":"Br J Oral Maxillofac Surg"},{"key":"B50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12859-023-05271-7","article-title":"EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates","volume":"24","author":"Fan","year":"2023","journal-title":"BMC Bioinf"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.141","article-title":"The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma","volume":"30","author":"Banerjee","year":"2011","journal-title":"Oncogene"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e21900","DOI":"10.1097\/MD.0000000000021900","article-title":"Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome: A meta-analysis","volume":"99","author":"Huang","year":"2020","journal-title":"Medicine"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000684","article-title":"The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth","volume":"23","author":"Setoguchi","year":"2010","journal-title":"Oncol Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2016.1208872","article-title":"Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors","volume":"15","author":"Wassef","year":"2016","journal-title":"Cell Cycle"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1101\/gad.269522.115","article-title":"Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis","volume":"29","author":"Wassef","year":"2015","journal-title":"Genes Dev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.6022","article-title":"Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial","volume":"41","author":"Puram","year":"2023","journal-title":"JCO"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1438021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T05:50:03Z","timestamp":1741672203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1438021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":57,"alternative-id":["10.3389\/fonc.2024.1438021"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1438021","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"article-number":"1438021"}}